CANF רווח למניה בשנים עשר החודשים האחרונים Can-Fite

Can-Fite BioPharma focuses on adenosine receptors for the treatment of oncology and psoriasis, awaiting the commercialization of late-stage clinical trial results. The current earnings per share for the last 12 months are visualized below, where -6.34 forms the current metric value. The strategy is based on the A3AR agonist platform, aimed at creating safe oral agents for the specialized pharmaceutical market.

Operational efficiency is determined by the ability to generate real cash flow. This indicator is calculated by dividing the total annual net income by the total number of outstanding shares, reflecting the earnings per share. For Can-Fite BioPharma (CANF), this parameter confirms the monetization of exclusive patent developments in oncology. Growth in earnings per share indicates the commercial success of unique drugs. The trailing 12-month earnings per share trend captures these fundamental trends.